JP2019528077A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528077A5
JP2019528077A5 JP2019510951A JP2019510951A JP2019528077A5 JP 2019528077 A5 JP2019528077 A5 JP 2019528077A5 JP 2019510951 A JP2019510951 A JP 2019510951A JP 2019510951 A JP2019510951 A JP 2019510951A JP 2019528077 A5 JP2019528077 A5 JP 2019528077A5
Authority
JP
Japan
Prior art keywords
polypeptide
host cell
chimeric
antigen
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019510951A
Other languages
English (en)
Japanese (ja)
Other versions
JP7500195B2 (ja
JP2019528077A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/048040 external-priority patent/WO2018039247A1/en
Publication of JP2019528077A publication Critical patent/JP2019528077A/ja
Publication of JP2019528077A5 publication Critical patent/JP2019528077A5/ja
Priority to JP2022057245A priority Critical patent/JP2022106714A/ja
Application granted granted Critical
Publication of JP7500195B2 publication Critical patent/JP7500195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019510951A 2016-08-23 2017-08-22 タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法 Active JP7500195B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022057245A JP2022106714A (ja) 2016-08-23 2022-03-30 タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378614P 2016-08-23 2016-08-23
US62/378,614 2016-08-23
PCT/US2017/048040 WO2018039247A1 (en) 2016-08-23 2017-08-22 Proteolytically cleavable chimeric polypeptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022057245A Division JP2022106714A (ja) 2016-08-23 2022-03-30 タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2019528077A JP2019528077A (ja) 2019-10-10
JP2019528077A5 true JP2019528077A5 (enExample) 2020-09-24
JP7500195B2 JP7500195B2 (ja) 2024-06-17

Family

ID=61245300

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019510951A Active JP7500195B2 (ja) 2016-08-23 2017-08-22 タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法
JP2022057245A Ceased JP2022106714A (ja) 2016-08-23 2022-03-30 タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022057245A Ceased JP2022106714A (ja) 2016-08-23 2022-03-30 タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法

Country Status (9)

Country Link
US (3) US11401332B2 (enExample)
EP (1) EP3504245A4 (enExample)
JP (2) JP7500195B2 (enExample)
KR (2) KR102637610B1 (enExample)
CN (1) CN109843929B (enExample)
AU (1) AU2017316649A1 (enExample)
CA (1) CA3034093A1 (enExample)
SG (2) SG11201901528RA (enExample)
WO (1) WO2018039247A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2618821A4 (en) 2010-09-24 2014-08-13 Brigham & Womens Hospital NANOSTRUCTURED GELS FOR CONTROLLED RELEASE OF CAPSUED MEDIUM
EP3258967A4 (en) 2015-02-20 2018-10-03 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
CN108367057B (zh) 2015-04-06 2022-11-22 赛通免疫股份有限公司 用于胶质母细胞瘤的egfr导向的car疗法
CN110225760B (zh) * 2016-09-15 2023-11-07 埃里西拉医疗公司 T细胞免疫疗法
CA3038475A1 (en) * 2016-09-28 2018-04-05 Immpact-Bio Ltd. A universal platform for car therapy targeting a novel antigenic signature of cancer
US11020410B2 (en) 2017-02-03 2021-06-01 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
AU2018269370B2 (en) * 2017-05-16 2025-06-05 The Johns Hopkins University Manabodies and methods of using
US11325957B2 (en) 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
GB201804291D0 (en) * 2018-03-16 2018-05-02 Evox Therapeutics Ltd Cell-mediated exosome delivery
JP7202689B2 (ja) * 2018-03-16 2023-01-12 サイトイミューン セラピューティクス, インコーポレイテッド 二重特異性抗体car細胞免疫療法
JP2021520352A (ja) 2018-04-04 2021-08-19 アリヴィオ セラピューティクス, インコーポレイテッド 生物製剤の制御送達用の自己組織化ゲルおよびその製造方法
EP3773632A4 (en) 2018-04-06 2022-05-18 The Regents of The University of California METHODS OF TREATMENT OF EGFRVIII-EXPRESSING GLIOBLASTOMA
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
CA3096200A1 (en) * 2018-04-06 2019-10-10 The Regents Of The University Of California Trans-antigen targeting in heterogeneous cancers and methods of use thereof
EP3774867A1 (en) * 2018-04-10 2021-02-17 Stichting Sanquin Bloedvoorziening Chimeric notch receptors
US20210317479A1 (en) 2018-09-06 2021-10-14 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
EP3876956A4 (en) 2018-11-08 2022-12-28 The Regents of The University of California SYSTEMS AND METHODS FOR TARGETING CANCER CELLS
EP3891286A4 (en) * 2018-12-06 2022-10-19 The Board of Trustees of the Leland Stanford Junior University Regulatable cell surface receptors and related compositions and methods
WO2020140973A1 (en) * 2019-01-03 2020-07-09 Nanjing Legend Biotech Co., Ltd. Modified immune cells expressing flagellin polypeptide
KR20220053587A (ko) * 2019-08-09 2022-04-29 에이투 바이오쎄라퓨틱스, 인크. 이형접합성 소실에 반응성인 세포 표면 수용체
US20220356225A1 (en) * 2019-09-24 2022-11-10 The Regents Of The University Of California Notch receptors with zinc finger-containing transcriptional effector
WO2021061856A1 (en) * 2019-09-24 2021-04-01 The Regents Of The University Of California Receptors with heterologous transmembrane domain
HRP20250135T1 (hr) * 2019-09-24 2025-03-28 The Regents Of The University Of California Notch receptori sa zglobnom domenom
WO2021061859A1 (en) * 2019-09-24 2021-04-01 The Regents Of The University Of California Novel receptors for ligand-dependent transcriptional regulation
CN110716044B (zh) * 2019-10-23 2023-04-18 郑州大学 一种用于食管鳞癌早期筛查和诊断的血清蛋白标志物、试剂盒及检测方法
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
CN110970090B (zh) * 2019-11-18 2021-06-29 华中科技大学 一种用于判断待处理多肽与阳性数据集肽段相似度的方法
CN115087466A (zh) * 2019-12-12 2022-09-20 森迪生物科学公司 用于细胞的调控装甲的方法和组合物
WO2021131944A1 (ja) * 2019-12-27 2021-07-01 国立大学法人神戸大学 癌遺伝子治療薬
CN115666726A (zh) * 2020-04-09 2023-01-31 加利福尼亚大学董事会 具有铰链结构域的人源化Notch受体
WO2021206910A1 (en) * 2020-04-09 2021-10-14 The Regents Of The University Of California Notch receptors with zinc finger-containing transcriptional effector
EP4168562A4 (en) * 2020-06-18 2024-07-24 Flagship Pioneering Innovations VI, LLC METHODS AND COMPOSITIONS FOR MODULATING CELLS AND CELL MEMBRANES
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
EP4097486A4 (en) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF POSITIVE CANCERS AT CEACAM
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス,インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022183056A1 (en) * 2021-02-26 2022-09-01 Salk Institute For Biological Studies Modulating regulatory t cell function in autoimmune disease and cancer
EP4314038A4 (en) * 2021-03-23 2025-01-29 The Regents of the University of California SYNTHETIC INTERMEMBRANE PROTEOLYSIS RECEPTORS FOR PERSONALIZED ANTIGEN-INDUCED TRANSCRIPTION REGULATION
WO2022204326A1 (en) * 2021-03-24 2022-09-29 The Regents Of The University Of California Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
CN113307859B (zh) * 2021-03-24 2022-03-01 深圳市新靶向生物科技有限公司 一种与乳腺癌驱动基因突变相关的抗原肽组合及其应用
IL311570A (en) 2021-10-14 2024-05-01 Arsenal Biosciences Inc Immune cells with common expression chain and logic gate systems
CN114107253B (zh) * 2021-12-17 2024-03-15 复旦大学附属华山医院 一种利用工程细胞进行基因编辑的系统及方法
CN114736308B (zh) * 2022-03-15 2022-12-27 四川宜美康科技有限公司 球虫抗原肽/il5的融合蛋白基因工程菌的制备及用途
CN117510615B (zh) * 2023-01-31 2025-01-07 上海恩凯细胞技术有限公司 SynNotch受体及其用途
WO2025076422A1 (en) * 2023-10-05 2025-04-10 The Regents Of The University Of California Regulated expression of card11-pik3r3 fusion protein

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
GB0112818D0 (en) 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
GB0220658D0 (en) 2002-09-05 2002-10-16 Lorantis Ltd Immunotherapy
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
WO2009040782A2 (en) 2007-09-28 2009-04-02 Royal College Of Surgeons In Ireland A method of assessing colorectal cancer status in an individual
CA2729602A1 (en) 2008-07-08 2010-01-14 Oncomed Pharmaceuticals, Inc. Notch1 receptor binding agents and methods of use thereof
EP3072961A1 (en) 2010-04-16 2016-09-28 Children's Medical Center Corporation Sustained polypeptide expression from synthetic, modified rnas and uses thereof
SG11201502598SA (en) 2012-10-02 2015-05-28 Sloan Kettering Inst Cancer Compositions and methods for immunotherapy
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
AU2014342020C1 (en) 2013-10-31 2019-09-05 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof
US9730935B2 (en) 2013-12-13 2017-08-15 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment
AU2015204766B2 (en) 2014-01-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
CA3190002A1 (en) 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
US10196608B2 (en) 2014-02-21 2019-02-05 Cellectis Method for in situ inhibition of regulatory T cells
WO2015130766A1 (en) * 2014-02-25 2015-09-03 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
US20170209492A1 (en) * 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
ES3034398T3 (en) 2014-08-28 2025-08-18 Bioatla Inc Conditionally active chimeric antigen receptors for modified t-cells
KR20170083534A (ko) * 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
CA2969659A1 (en) 2014-12-09 2016-06-16 Sapporo Medical University Tumor antigen peptide
WO2016138034A1 (en) 2015-02-24 2016-09-01 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
US11400116B2 (en) 2016-05-06 2022-08-02 The Regents Of The University Of California Systems and methods for targeting cancer cells

Similar Documents

Publication Publication Date Title
US12030953B2 (en) Chimeric antigen receptors, compositions, and methods
JP2020503885A5 (enExample)
JP6784687B2 (ja) 結合誘発型転写スイッチ及びその使用方法
JP2019519227A5 (enExample)
JP2018519296A5 (enExample)
JP2023506452A5 (enExample)
IL275743A (en) New bispecific format suitable for use in high-through-put screening
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
JP2021525530A5 (enExample)
JP2019514361A5 (enExample)
JP2017518037A5 (enExample)
JP2020512820A5 (enExample)
JP2017522891A5 (enExample)
JP2019521643A5 (enExample)
JP2018528786A5 (enExample)
JP2024023228A5 (enExample)
JP2017506882A5 (enExample)
JP2018529327A5 (enExample)
RU2015144098A (ru) Четырехвалентные биспецифические антитела
JP2022513116A5 (enExample)
RU2019134273A (ru) Конструкты индуктора презентации антигена опухоли и их использование
JP2015528003A5 (enExample)
JP2017501702A5 (enExample)
JP2019530440A5 (enExample)
JP2023503840A5 (enExample)